Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics ...

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) ...

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...

In the chart below, we highlight the unlikely scenarios needed to ... Lilly have set the bar for efficacy and side effect ...

Global GLP-1 Analogues Market is valued at approximately USD 35.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 33% over the forecast period 2024-2032. Read the ...

Last month, Eli Lilly announced it would reduce the cost of the lowest dose of its drug Zepbound to around $400 a month. It also launched its own telehealth company, LillyDirect. Readdy ...

Real-time index price for TSX Composite Index (TXCX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

If anything, the four-week supply of the 2.5 mg Zepbound single-dose vial at $399 (self-pay) is not too far from HIMS' compounded GLP-1 injectables from $199 monthly (based on a 12-month plan).

Compounding pharmacies have used a legal provision that allows them to make knockoff versions of Lilly’s Zepbound and Mounjaro while they are in a shortage. While Lilly has raised questions ...

In the interview, Lee said he was looking at a handful of charts that back up his bullish long-term prediction. Here are the four charts Lee shared with Business Insider that show why the already ...

Wegovy, Zepbound and other cutting-edge weight-loss ... warnings this year about compounded semaglutide, which has caused dosing errors that resulted in severe nausea, vomiting, hypoglycemia ...